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BACKGROUND: Somatic mutations in phosphoinositide-3-kinase catalytic subunit alpha (PIK3CA) are frequent in breast tumours and
have been associated with oestrogen receptor (ER) expression, human epidermal growth factor receptor-2 overexpression, lymph
node metastasis and poor survival. The goal of this study was to evaluate the association between inherited variation in this oncogene
and risk of breast cancer.
METHODS: A single-nucleotide polymorphism from the PIK3CA locus that was associated with breast cancer in a study of Caucasian
breast cancer cases and controls from the Mayo Clinic (MCBCS) was genotyped in 5436 cases and 5280 controls from the Cancer
Genetic Markers of Susceptibility (CGEMS) study and in 30 949 cases and 29 788 controls from the Breast Cancer Association
Consortium (BCAC).
RESULTS: Rs1607237 was significantly associated with a decreased risk of breast cancer in MCBCS, CGEMS and all studies of white
Europeans combined (odds ratio (OR)¼ 0.97, 95% confidence interval (CI) 0.95–0.99, P¼ 4.6 103), but did not reach
significance in the BCAC replication study alone (OR¼ 0.98, 95% CI 0.96–1.01, P¼ 0.139).
CONCLUSION: Common germline variation in PIK3CA does not have a strong influence on the risk of breast cancer
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Phosphatidylinositol-3 kinases (PI3Ks) constitute a lipid kinase
family integral to signalling pathways that regulate many cancer-
related processes, including cell proliferation, adhesion, apoptosis,
survival and motility (Fruman et al, 1998; Cantley, 2002).
Alteration of PI3K family members, such as amplification of the
phosphoinositide-3-kinase catalytic subunit alpha (PIK3CA) onco-
gene on chromosome 3q26 that encodes the p110a catalytic
subunit of PI3K, are commonly observed in human cancers.
Amplification and overexpression of PIK3CA results in increased
production of the phosphatidylinositol-3,4,5-triphosphate second
messenger, hyperactivation of the PI3K/AKT pathway, and
stimulation of cellular transformation and tumour progression
(Shayesteh et al, 1999; Ma et al, 2000; Fresno Vara et al, 2004; Saal
et al, 2005; Samuels and Ericson, 2006). Somatic mutations in
PIK3CA are also common in colon (18–32%), gastric (4–25%),
endometrial (36%), liver (36%), brain (27%) and breast (18–40%)
tumours (Bachman et al, 2004; Campbell et al, 2004; Samuels et al,
2004; Karakas et al, 2006; Ligresti et al, 2009). Functional analyses
have shown that many of these mutations activate PIK3CA
enzymatic activity and stimulate downstream AKT signalling,
promoting growth factor-independent growth and metastasis
(Samuels et al, 2004; Samuels and Ericson, 2006).
In breast tumours, PIK3CA mutations have been consistently
associated with ER-positive and human epidermal growth factor
receptor-2 (HER2)-positive tumour status (Saal et al, 2005; Li et al,
2006; Perez-Tenorio et al, 2007; Stemke-Hale et al, 2008)
(Saal et al, 2005; Perez-Tenorio et al, 2007). The correlation
between these mutations and breast cancer prognosis is less clear,
with several studies reporting associations between PIK3CA
mutations and lymph node metastasis and worse overall and
breast cancer-specific survival (Saal et al, 2005; Li et al, 2006; Lai
et al, 2008; Aleskandarany et al, 2010), whereas other studies have
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reported associations with longer survival particularly among
patients with ER-positive, HER2-negative tumours (Perez-Tenorio
et al, 2007; Kalinsky et al, 2009; Loi et al, 2010).
Although the pathological and clinical significance of PIK3CA
somatic mutations has been well studied, the contribution of
inherited variation in this important oncogene to risk of breast
cancer is unknown. Here we investigated the influence of germline
variation in PIK3CA on breast cancer risk.
MATERIALS AND METHODS
Mayo clinic breast cancer study
The details of the Mayo Clinic Breast Cancer case–control Study
(MCBCS) have been described previously (Wang et al, 2008).
Briefly, cases were comprised of Caucasian women with invasive
breast cancer diagnosed within 6 months of ascertainment with no
prior history of cancer. Controls were comprised of Caucasian
women visiting the Mayo Clinic for general medical exams in the
Department of Internal Medicine with no prior history of cancer.
Participants were recruited under an Institutional Review Board
approved protocol. A total of 798 cases and 843 controls were
utilised for stage 1 genotyping (Table 1).
Replication studies
The Cancer Genetic Markers of Susceptibility (CGEMS) breast
cancer case–control study and 26 case–control studies from
Breast Cancer Association Consortium (BCAC) contributed data to
these analyses (described in Supplementary Table 1). Stage 1 of the
CGEMS GWAS included 1145 cases and 1142 controls of self-
reported white European ancestry (Thomas et al, 2009), whereas
the combined Stage 1 and 2 of CGEMS included a total of 5436
cases and 5280 controls (Table 1). The BCAC replication was
comprised of 24 studies of women of primarily European descent
(Supplementary Table 1), 1702 additional samples from MCBCS
and two studies (SEBCS and TBCS) of women from Southeast Asia
(Table 1). Final combined analyses included 35 991 breast cancer
cases and 35 153 controls of white European ancestry, as well as
2183 breast cancer cases and 1469 controls of Asian ancestry.
Study participants were recruited under protocols approved by the
institutional review board at each institution and all subjects
provided written informed consent.
Genotyping
Four haplotype-tagging single-nucleotide polymorphisms (SNPs)
within PIK3CA (rs13320527, rs3729692, rs1607237, rs9838117)
were selected (r240.80 in European–American genotype data
from HapMap release 21). A total of 1741 Mayo Clinic samples
(798 cases, 843 controls and 100 duplicates) were genotyped on
custom oligo pool assays at Illumina Corporation (San Diego, CA,
USA) using the Illumina GoldenGate assay. All SNPs had genotype
call rates495%. Concordance between duplicate samples was 100%.
Genotyping of rs1607237 in CGEMS and BCAC was performed using
a TaqMan allelic discrimination assay or the Sequenom platform
(Sequenom, San Diego, CA, USA) via standard protocols. Genotyp-
ing concordance was verified with internal duplicates and overall
data quality was ensured using independent genotyping of 96 CEU
samples by each genotyping center (Garcia-Closas et al, 2008). All
studies met the specified criteria for call rate (495%).
Pathology and tumour markers
The collection of pathology and tumour marker information for
BCAC has been described previously (Yang et al, 2011). Pathology
data were also available for 900 CGEMS subjects. Briefly, studies
provided information on histopathological subtype, grade of
differentiation, tumour size, nodal involvement and stage at
diagnosis of breast tumours. All studies except BBCS, GC-HBOC
and HMBCS provided data on ER and progesterone receptor (PR)
status of tumours, and 12 studies provided data on HER2
(Supplementary Table 2). ER/PR status was most commonly
defined using data from medical records. Oestrogen receptor and
PR negative status was defined as o10% of the tumour cells
stained. Human epidermal growth factor receptor-2-negative
status was typically defined as a score of 0 or 1þ on a HER2
immunohistochemistry (IHC) scale of 0–3þ .
Statistical methods
Evidence of departure from Hardy–Weinberg equilibrium (HWE)
was assessed in controls using a goodness of fit test and none
was observed (HWE PX0.001). Single-nucleotide polymorphism
associations were tested using unconditional logistic regression
adjusting for age and state of residence in a log-additive model.
We also calculated odds ratios (ORs) and 95% confidence intervals
(CIs) separately for heterozygotes and rare homozygotes.
The association between rs1607237 and breast cancer risk in stage
1 of the CGEMS GWAS was evaluated as previously described
(Thomas et al, 2009). Associations with breast cancer risk in the
BCAC studies and the combined BCAC, MCBCS and CGEMS
studies were evaluated using unconditional logistic regression
adjusting for study center. A likelihood ratio test of heterogeneity
by age groups was not significant (P¼ 0.10), and further
adjustment for age did not change the results. Analyses of
pathology-specific subsets of cases were conducted using poly-
tomous regression with controls as the reference outcome,
adjusting for study site.
Table 1 Studies contributing to evaluation of associations between
rs1607237 and breast cancer risk
Studya Country Cases n (%) Controls n (%)
ABCFS Australia 1199 (3.1) 438 (1.2)
ABCS The Netherlands 1465 (3.8) 548 (1.5)
BBCC Germany 1060 (2.8) 994 (2.7)
BBCS UK 1153 (3.0) 831 (2.3)
BIGGS Ireland 1060 (2.8) 900 (2.5)
CGEMSb USA 5436 (14.2) 5280 (14.4)
CNIO-BCS Spain 752 (2.0) 823 (2.2)
GC-HBOC Germany 864 (2.3) 1224 (3.3)
GENICA Germany 1013 (2.7) 1012 (2.8)
GESBC Germany 563 (1.5) 564 (1.5)
HABCS Germany 1046 (2.7) 998 (2.7)
HMBCS Belarus 1760 (4.6) 1015 (2.8)
KARBAC Sweden 812 (2.1) 863 (2.4)
kConFab/AOCS Australia/New Zealand 566 (1.5) 899 (2.5)
KBCP Finland 485 (1.3) 427 (1.2)
MARIE Germany 2754 (7.2) 5302 (14.5)
MBCSG Italy 739 (1.9) 1231 (3.4)
MCBCSc USA 1789 (4.7) 1554 (4.2)
MCCS Australia 679 (1.8) 751 (2.1)
NC-BCFR USA 388 (1.0) 154 (0.4)
OBCS Finland 544 (1.4) 509 (1.4)
OFBCR Canada 1170 (3.1) 329 (0.9)
SBCS UK 1217 (3.2) 1201 (3.3)
SEARCH UK 6520 (17.1) 6779 (18.5)
SEBCSd Korea 1732 (4.5) 1178 (3.2)
TBCSd Thailand 451 (1.2) 291 (0.8)
UCIBCS USA 957 (2.5) 527 (1.4)
Total 38 174 (100) 36 622 (100)
aSee Supplementary Table 1 for definition of study acronyms. bStage 2: Cancer
Genetic Markers of Susceptibility study. cIncludes Stage 1: Mayo Clinic Breast Cancer
Study. dAsian case–control studies.
PIK3CA common variants and breast cancer risk
KN Stevens et al
1936
British Journal of Cancer (2011) 105(12), 1934 – 1939 & 2011 Cancer Research UK
G
e
n
e
tic
s
a
n
d
G
e
n
o
m
ic
s
RESULTS
Of four PIK3CA haplotype-tagging SNPs, rs1607237 was signifi-
cantly associated with risk of breast cancer in MCBCS (OR¼ 0.85,
95% CI 0.73–0.98, P¼ 0.023; Table 2, Supplementary Figure 1).
Next we evaluated associations between rs1607237 and breast
cancer risk in 1145 cases and 1142 controls genotyped in stage 1 of
the CGEMS breast cancer GWAS (Thomas et al, 2009). Rs1607237
was significantly associated with breast cancer risk (heterozygous
OR¼ 1.12, homozygous OR¼ 0.79, score P¼ 0.017). To provide a
more stable estimate of risk in this population, 8429 additional
CGEMS subjects were genotyped for rs1607237. In all 5436 cases
and 5280 controls from stage 1 and 2 of CGEMS, rs1607237 was
strongly associated with a decrease in breast cancer risk
(OR¼ 0.92, 95% CI 0.88–0.98, P¼ 0.0050; Table 2).
This finding provided the rationale for further evaluation of this
SNP in 23 BCAC studies involving women of European ancestry
(28 766 cases, 28 319 controls), and two BCAC studies of Asian
women (2183 cases, 1469 controls; Table 1). Rs1607237 was not
significantly associated with breast cancer risk in the 23 BCAC
studies of women of European ancestry (OR¼ 0.98, 95% CI 0.96–
1.01, P¼ 0.139) or in the two Asian BCAC studies (OR¼ 1.05, 95%
CI 0.94–1.16, P¼ 0.39; Table 2). However, when combining all
genotype data from the three stages of this study (MCBCS, CGEMS
and BCAC; Supplementary Table 3), rs1607237 was significantly
associated with risk of breast cancer (OR¼ 0.97, 95% CI 0.95–0.99,
P¼ 9.5 103). Similarly, a significant association was observed
when considering only women of European ancestry in the
combined analysis (OR¼ 0.97, 95% CI 0.95–0.99, P¼ 4.6 103;
(Table 2). There was no evidence of heterogeneity by study site
among the 25 Caucasian studies (P¼ 0.14; Supplementary Figure 2).
To further understand the association with breast cancer, we
restricted the analysis to women with invasive breast cancer.
Rs1607237 was associated with a reduced risk of invasive breast
cancer (OR¼ 0.97, 95% CI 0.95–0.99, P¼ 0.012; Table 2), whereas
no association with risk of ductal carcinoma in situ was observed
(OR¼ 0.93, 95% CI 0.85–1.02, P¼ 0.12). In addition, we explored
differences in PIK3CA SNP associations in the combined data set
by tumour subtype (Supplementary Table 4). The rs1607237
variant was not associated with any subtypes defined by ER, PR or
HER2 status, although it is important to note the reduction in
sample size when restricting to these tumour subtypes.
DISCUSSION
Here we report an association between inherited variation in the
oncogene PIK3CA and risk of breast cancer in a large, three-stage
analysis utilising nearly 75 000 subjects from 27 case–control
study studies. We show that rs1607237 is significantly associated
with a small decrease in breast cancer risk (OR¼ 0.97, 95% CI
0.95–0.99, P¼ 9.5 103) in all studies combined and when
considering only women of European ancestry in the combined
studies (OR¼ 0.97, 95% CI 0.95–0.99, P¼ 4.6 103). However,
the association did not achieve significance in the large third stage
involving only BCAC studies. Although the first two stages of our
analysis suggest an association between PIK3CA and breast cancer
risk, our inability to confirm this finding in the BCAC studies
suggests that the result should be interpreted with caution.
We further explored the linkage disequilibrium patterns in the
PIK3CA coding and promoter regions to better understand the
relationship between rs1607237 and other variation in this region.
Rs1607237 was not in strong linkage disequilibrium with two non-
synonymous polymorphic variants in the coding region of
PIK3CA, rs1051399 (r2¼ 0.0060) and rs3729680 (r2¼ 0.034), which
had been genotyped in HapMap samples of European ancestry.
However, an additional 18 non-synonymous variants were either
not polymorphic or had not been genotyped in the HapMap
samples, making inference about the relationship between
rs1607237 and all variants of unknown significance in the PIK3CA
coding region difficult. In addition, two PIK3CA promoter SNPs
were in low LD with rs1607237 (rs9831234, r2¼ 0.16; rs2865084,
r2¼ 0.038). However, it remains possible that PIK3CA promoter
SNPs that were not captured in this study are related to breast
cancer risk.
It is also important to note that the effect estimate for rs1607237
in the BCAC replication studies and in the overall BCAC, MCBCS
and CGEMS studies is quite small (OR¼ 0.97). This limits our
statistical power to detect significant associations in these studies
despite the large sample size, particularly in analyses utilising
pathology information that is available for only a subset of
subjects. Similarly, we had limited power to detect associations in
the original MCBCS study with the three non-significant PIK3CA
SNPs. Thus, it remains possible that evaluation of these variants in
the larger BCAC cohort might detect associations with risk. While
the effect of rs1607237 on risk is small, the association between
inherited variation in this important oncogene and breast cancer
risk does provide valuable biological insight into the development
of this disease. Validation of rs1607237 in GWAS studies from
other large collaborative groups and additional studies by BCAC
with detailed pathology information are necessary to confirm this
association. Functional evaluation of this variant is needed to fully
understand the relationship between inherited PIK3CA variation
and breast cancer risk.
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Combined analysis 35 991 35 153 0.97 (0.95–0.99) 0.0046 0.97 (0.93–1.00) 0.94 (0.90–0.98)
Invasive 33 660 34 988 0.97 (0.95–0.99) 0.012 0.97 (0.94–1.00) 0.95 (0.90–0.99)
DCIS 1159 16 889 0.93 (0.85–1.02) 0.12 0.98 (0.85–1.12) 0.84 (0.70–1.02)
Abbreviations: BCAC¼ Breast Cancer Association Consortium; CGEMS¼Cancer Genetic Markers of Susceptibility; CI¼ confidence interval; DCIS¼ ductal carcinoma in situ;
MCBCS¼Mayo Clinic breast cancer case–control study; OR¼ odds ratio.
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